Skip to main
AUTL
AUTL logo

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics PLC is advancing its clinical-stage pipeline of next-generation programmed T-cell therapies, with Obe-cel positioned to expand its label and potentially outperform standard-of-care CAR-T therapies. The company anticipates achieving gross margins of 60-70% through enhanced manufacturing utilization and process improvements, which could positively impact overall financial performance. Additionally, the demonstrated safety and mortality benefits of its Aucazyl product in real-world applications further solidify Autolus’s competitive edge in the treatment landscape for cancer therapy.

Bears say

Autolus Therapeutics's stock is facing a negative outlook primarily due to anticipated flat sales in Q3 2025, influenced by changes in CMS reimbursement policies, raising concerns about the stability of revenue streams. Additionally, the early results from the SLDAI-2K study suggest limited effectiveness, with only two out of three patients showing significant clinical improvements, which may hinder the company's ability to meet its forecasts for CAR-T therapeutics production. The emergence of complications in patient outcomes, including relapse and minimal residual disease, further contributes to uncertainties regarding the efficacy and commercial viability of its therapies.

Autolus Therapeutics (AUTL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.